Wealth Alliance Advisory Group LLC Sells 15,380 Shares of Pfizer Inc. $PFE

Wealth Alliance Advisory Group LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 48.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,248 shares of the biopharmaceutical company’s stock after selling 15,380 shares during the period. Wealth Alliance Advisory Group LLC’s holdings in Pfizer were worth $394,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Bessemer Group Inc. lifted its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 13,228 shares during the period. Capital Advisors Inc. OK lifted its position in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after buying an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer during the first quarter valued at $8,283,000. Westbourne Investments Inc. purchased a new position in Pfizer during the first quarter valued at $2,411,000. Finally, Alta Advisers Ltd lifted its position in Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 13,100 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $23.91 on Friday. The stock has a 50-day moving average price of $24.79 and a 200-day moving average price of $24.28. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market cap of $135.94 billion, a PE ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer’s payout ratio is 91.49%.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Finally, Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.